272 related articles for article (PubMed ID: 10436138)
1. Low-molecular-weight heparin should replace unfractionated heparin in the management of acute coronary syndromes.
Zed PJ
J Thromb Thrombolysis; 1999 Aug; 8(2):79-87. PubMed ID: 10436138
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparins and coronary artery disease.
Zed PJ
Curr Cardiol Rep; 2000 Jan; 2(1):61-8. PubMed ID: 10980874
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes.
Magee KD; Sevcik W; Moher D; Rowe BH
Cochrane Database Syst Rev; 2003; (1):CD002132. PubMed ID: 12535430
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparins in the management of acute coronary syndromes.
Zed PJ; Tisdale JE; Borzak S
Arch Intern Med; 1999 Sep; 159(16):1849-57. PubMed ID: 10493315
[TBL] [Abstract][Full Text] [Related]
5. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
Kaul S; Shah PK
J Am Coll Cardiol; 2000 Jun; 35(7):1699-712. PubMed ID: 10841215
[TBL] [Abstract][Full Text] [Related]
6. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M
Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
Lepor NE
Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
[TBL] [Abstract][Full Text] [Related]
8. Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.
Turpie AG
Can J Cardiol; 1998 Aug; 14 Suppl E():20E-23E. PubMed ID: 9779029
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulants in acute coronary syndromes.
Turpie AG
Am J Cardiol; 1999 Sep; 84(5A):2M-6M. PubMed ID: 10505536
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin in unstable coronary artery disease.
Wallentin L
Expert Opin Investig Drugs; 2000 Mar; 9(3):581-92. PubMed ID: 11060697
[TBL] [Abstract][Full Text] [Related]
11. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
Bosanquet N; Jönsson B; Fox KA
Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436
[TBL] [Abstract][Full Text] [Related]
12. Heparin versus placebo for non-ST elevation acute coronary syndromes.
Andrade-Castellanos CA; Colunga-Lozano LE; Delgado-Figueroa N; Magee K
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD003462. PubMed ID: 24972265
[TBL] [Abstract][Full Text] [Related]
13. Enoxaparin: an update of its clinical use in the management of acute coronary syndromes.
Ibbotson T; Goa KL
Drugs; 2002; 62(9):1407-30. PubMed ID: 12076195
[TBL] [Abstract][Full Text] [Related]
14. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
15. Is the use of unfractionated heparin in acute coronary syndrome outmoded?
Chiquette E; Chilton R
Curr Atheroscler Rep; 2004 Mar; 6(2):94-100. PubMed ID: 15023292
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
[TBL] [Abstract][Full Text] [Related]
17. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.
Moser LR; Kalus JS
Ann Pharmacother; 2004 Dec; 38(12):2094-104. PubMed ID: 15536140
[TBL] [Abstract][Full Text] [Related]
18. The use of low-molecular-weight heparin in acute coronary syndromes.
Fiorini DM
AACN Clin Issues; 2001 Feb; 12(1):53-61. PubMed ID: 11288329
[TBL] [Abstract][Full Text] [Related]
19. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic therapy in acute coronary syndromes: key notes from ESSENCE and TIMI 11B.
Fox KA
Semin Hematol; 2001 Apr; 38(2 Suppl 5):67-74. PubMed ID: 11449345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
